Replies to post #44021 on Innovation Pharmaceuticals Inc (IPIX)

[redwing992006]

nice post. They assess the risk / reward ratio for these drugs. If there is a slight risk of HTN with the high reward of treating infection that is resistant to other antibiotics, then B will be a success. Not sure about P and psoriasis as far as the risk. If Kevitirin can halt or reverse neoplasms / metastasis with low or no toxicity, it is obvious that this will be huge. ( both for investors as well as cancer patients)

[I Need Help]

Enjoyed your post.

TOX is so very important. Just look at what has happened to ARIA this week.

I like the TOX profiles on all CTIX products I am aware of.

One other major advantage concerning B is that being an antibiotic it will have limited dosing and treatments per patient. Unlike cancer drugs, B would probably only be administered once, twice, or three times per patient per infection. Cancer drugs may require many doses per patient over the cancer treatment. B looking good.